The strongest dose of Mounjaro can lead to nearly twice as much weight loss as Ozempic in 40 weeks
C.IglehartJ
Xie L, Lopes Almeida Gomes L, Stone CJ, Faden DF, Werth VP
This protective association has been repeatedly observed, linking GLP-1RA use to lower risks of POAG, ocular hypertension, and the need for first-line glaucoma treatment in large cohorts of T2DM patients [105,106,107]
Clinical outcomes with bioactive agents alone or in combination with grafting or guided tissue regeneration
Clinical studies of GLP-1RAs generally do not demonstrate sustained increases in resting energy expenditure, reinforcing the view that appetite suppressionnot thermogenesisis the dominant driver of weight loss ( Importantly, the physiological ceiling on BAT-mediated thermogenesis implies that increasing energy expenditure is unlikely to offset the metabolic adaptation associated with rapid weight loss